胰激肽原酶联合保肾康治疗糖尿病肾病疗效观察

目的观察胰激肽原酶联合保肾康治疗糖尿病肾病的疗效。方法选择符合诊断标准的2型糖尿病患者50例,在血糖控制基本正常的基础上,口服胰激肽原酶及保肾康,疗程3个月,观察治疗效果。结果治疗后24h尿白蛋白排泄率(UAER)明显下降,与治疗前相比有显著差异(P<0.05)。结论胰激肽原酶联合保肾康对早期糖尿病肾病有显著疗效,能明显减少尿蛋白,

Objective To observe curative effect of kallidinogenase combined with ferulaic acid piperazine in diabetic nephropathy.Methods 50 diabetes patients consisting with diagnostic criteria were treated with kallidinogenase combined with ferulaic acid piperazine by take orally at the base of good blood glucose control,to observe curative effect after 3 months.Results The urinary albumin excretion rate in 24 hours of post-treatment was significantly lower than that of prior treatment（P0.05）.Conclusion The treatments of kallidinogenase combined with ferulaic acid piperazine in earlier period diabetic nephropathy had significant curative effect,and could decrease urine protein obviously.